The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...

In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in ...

A nasal spray, referred to as nasal anti-CD3, could be the first FDA-approved treatment for traumatic brain injury, or TBI, that can be easily administered with no serious side effects ...

Introduction Anti-CD3 antibody binds to the CD3/TCR complex on the wall of T lymphocytes and results in their activation. This leads to the release of various cytokines including tumour necrosis ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Intranasal administration of the anti-CD3 mAb to mice immediately (within 4–6 hours) or 3 days after TBI reduced CNS damage and behavioural deficits, such as impaired motor function and spatial ...

A NASAL spray containing an anti-CD3 monoclonal antibody has shown promising results in ameliorating traumatic brain injury (TBI) in a mouse model, reducing central nervous system damage and improving ...

(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...